-
US and Iran set for new talks after delay and deadly strikes
-
'Fired up' Spain ready to hit back, says De la Fuente
-
Germany into World Cup last 32 after late comeback, Dutch thrash Sweden
-
Germany come from behind to beat Ivory Coast and reach World Cup last 32
-
Albanian protests against Trump-linked resort swell
-
Clark clings to US Open lead as Scheffler charges
-
Burn dons cowboy boots as England unwind at World Cup
-
Miotti kicks Montpellier past Stade Francais into Top 14 final
-
France's Saliba says playing through the pain at World Cup
-
Counter-terror cops probe suspected anti-Muslim 'attacks' in Edinburgh
-
Bagnaia scorches to Czech MotoGP sprint victory, Bezzecchi suspended
-
Clark begins with bogey as McIlroy charges at US Open
-
Bolivia declares state of emergency, deploys military to quell protests
-
Specter of military escalation hangs over Colombia vote
-
Heavy metal: French town hosts medieval combat cage fights
-
Dutch swat Sweden as Germany, Ivory Coast eye World Cup knockout rounds
-
Netherlands thump Sweden in Houston to get World Cup liftoff
-
Scheffler opens with bogeys while McIlroy pars at windy US Open
-
Brazil turn corner but tougher World Cup tests await
-
Ronaldinho coming out of retirement to join Italian 3rd division side
-
Cerundolo sees off Nakashima to set up Queen's final with Paul
-
Real Madrid say no contact with Bayern's Olise
-
Fritz takes down Zverev again to reach Halle final
-
Heartbreak for Japanese ace Satono Reve as Almeraq wins Royal Ascot thriller
-
Hendy quick-fire double sweeps Northampton to Prem title
-
Injured Doris out of Ireland's Nations Championship squad
-
'Not ridiculous': US dreams of World Cup glory after big wins
-
Kolbe star goal kicker as Springboks put 80 past Barbarians
-
Pogacar pips Van der Poel to Swiss Tour TT win
-
Bolivia declares state of emergency and begins removing protester roadblocks
-
Ukraine's Zelensky, top officials return Polish awards in WWII row
-
Cerundolo sees off Nakashima to reach Queen's final
-
Jamieson double rocks England at start of record run-chase
-
Pegula powers past Sabalenka to reach Berlin final
-
Funeral for art giant David Hockney already taken place: publicist
-
Krishna and Jaiswal power India to ODI sweep against Afghanistan
-
Red heat alert issued for third of France, alcohol banned at music festival
-
Bagnaia scorches to Czech MotoGP sprint victory, Bezzecchi crashes
-
Trump escalates spat with Italy’s Meloni over G7 photo claim
-
New Zealand set England record 463 to win second Test
-
Driver killed, 28 in hospital as UK train collision probed
-
Diplomats hold US-Iran preparatory discussions at Swiss retreat
-
New Zealand pile on the runs to leave England facing record chase in 2nd Test
-
Shahidi hits ton but India bowl out Afghanistan for 218
-
Court bans Spanish PM's wife from leaving country
-
Israel strikes south Lebanon despite truce announced with Hezbollah
-
Japan's Ogura smashes own track record to take Czech MotoGP pole
-
Hurricanes blow away Chiefs in record-breaking Super Rugby final
-
Germany meet Ivory Coast in high-stakes World Cup clash, Sweden face Dutch
-
Ancient Greek theatre revives legendary Callas opera Medea
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
E.Raimundo--PC